3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
4
Active not recruiting
3
Terminated
2
Enrolling by invitation
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
10
Neoplasms
5
Neoplasm Metastasis
5
Adenocarcinoma
3
Stomach Neoplasms
2
Colorectal Neoplasms
2
Brain Neoplasms
2
Meningeal Carcinomatosis
1
HER2-positive Breast Cancer
1
Gastrointestinal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Carboplatin
341
Paclitaxel
262
Cisplatin
233
Pemetrexed
226
Docetaxel
206
Erlotinib Hydrochloride
193
Gemcitabine
178
pembrolizumab
137
Bevacizumab
121
Radiotherapy
118
Nivolumab
84
Gefitinib
73
Vinorelbine
64
Cetuximab
58
atezolizumab
47
Afatinib
46
durvalumab
44
osimertinib
41
Radiosurgery
35
Ipilimumab
34
Drug Therapy
32
Taxes
30
Albumin-Bound Paclitaxel
29
130-nm albumin-bound paclitaxel
29
Surgical Procedures, Operative
28
Etoposide
25
Irinotecan
24
Sorafenib
21
Cyclophosphamide
20
Radiation
19
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Carcinoma, Non-Small-Cell Lung
×
trastuzumab deruxtecan
×
Clear all
NCT04644237
2025-11-21
DESTINY-LUNG02
Daiichi Sankyo
Phase 2
Completed
152 enrolled
22 charts